Wan Amir-Jeffery Bin Wan Abdul Majid

Chief Operating Officer/Chief Commercial Officer, Duopharma Biotech Berhad


49 years




  • Bachelor of Business Administration – International Trade, University of Central Arkansas, United States of America
  • Senior Management Development Program, Harvard Business School, United States of America

Working Experience and Occupation

Wan Jeffery joined Duopharma Biotech as Chief Strategy Officer in September 2016, responsible for business development, Halal initiatives and Government Relations and Ethical Classic government business sales. He was appointed as Chief Operating Officer in September 2018 with additional responsibilities in Ethical Classic Private sales and Corporate Communication added to his portfolio. In 2020, Wan Jeffery was also appointed as Chief Commercial Officer when he took on board the Ethical Specialty business. Subsequently in 2021, he also took on the International Business Department commercial role, and as such, handles the entire commercial business of the Group.

Wan Jeffery has wide-ranging experience in the development of biotechnology and pharmaceutical industries. He launched his career in 1997 in a marine and environmental consulting firm, Sea Resources Management (SRM) Sdn. Bhd., leaving in 2007 to join Malaysian Biotechnology Corporation (BiotechCorp) Sdn. Bhd. As a Lead Business Analyst in the Biomedical Business Development and Investment Division, he acquired extensive knowledge and expertise in identifying, structuring and securing biomedical investment projects, especially in the biopharma and pharmaceutical industries. He was promoted to Vice- President within the same division in 2008.

In 2013, Wan Jeffery left BiotechCorp and joined Johor Biotechnology & Biodiversity Corporation and J-Biotech Holdings Sdn. Bhd as Chief Executive Officer (“J-Biotech”), responsible for developing and implementing key Johor state bioeconomy and biotech initiatives. He left J-Biotech in August 2016 to join Duopharma Biotech. Wan Jeffery is a member of the Institute of Corporate Directors Malaysia (ICDM). He is a member of Duopharma Biotech’s Group Management Committee.